iPS Cell-Derived Natural Killer Cell Production for Tumoricidal Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods face challenges in maintaining the tumor-targeting and tumoricidal capabilities of natural killer cells during culture and expansion, limiting their application in immunotherapy.
Innovation Solution
A method involving the use of GSK-3 and ROCK inhibitors to differentiate induced pluripotent stem cells into natural killer cells, with the inclusion of TGFβ receptor inhibitors and specific chimeric antigen receptors (CARs) to enhance tumor targeting, using viral and non-viral vectors for CAR expression, and culturing with growth factors to expand lymphocyte progenitor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If natural killer cells are cultured and expanded for immunotherapy, then the quantity of cells increases, but the tumor-targeting and tumoricidal capabilities deteriorate
Solution Approach 1:
The patent applies preliminary action by differentiating iPS cells into NK cells before immunotherapy treatment. The differentiation process is performed in advance using specific growth factors and cytokines to ensure the NK cells possess tumor-targeting capabilities before being deployed for treatment, thereby maintaining reliability while achieving quantity expansion
Solution Approach 2:
The patent utilizes parameter changes by manipulating culture conditions including growth factors (SCF, TPO, IL-7, hFlt3L), cytokines, and inhibitor concentrations during the differentiation and expansion process. These parameter adjustments maintain NK cell functionality and tumor-targeting capabilities while achieving sufficient cell quantity for therapy
2Manufacturing precision
If iPS cells are differentiated into natural killer cells, then the purity of natural killer cells increases, but the complexity of the differentiation process increases
Solution Approach 1:
The patent applies segmentation by dividing the differentiation process into distinct stages: embryoid body formation, hematopoietic progenitor cell generation, lymphocyte progenitor cell development, and natural killer cell differentiation. Each stage uses specific growth factors and inhibitors to achieve high purity NK cells while managing process complexity through systematic progression
Solution Approach 2:
The patent employs intermediary substances including growth factors (SCF, TPO, IL-7, hFlt3L), cytokines, and inhibitors (GSK-3 inhibitor, ROCK inhibitor, TGFβ receptor inhibitor) that mediate between iPS cells and mature NK cells. These intermediaries facilitate controlled differentiation and enable high purity NK cell production while simplifying the overall process through defined molecular pathways
Data Source
AI summary
The present invention provides a method for producing a natural killer cell from an iPS (Induced pluripotent stem) cell, comprising steps of: (i) contacting an iPS cell with a composition comprising a GSK-3 inhibitor and a ROCK inhibitor to obtain an embryoid body, (ii) contacting the embryoid body with a composition comprising a TGFβ receptor inhibitor to obtain a hematopoietic progenitor cell, (iii) culturing the hematopoietic progenitor cell to obtain a lymphocyte progenitor cell, and (iv) differentiating and expanding the lymphocyte progenitor cells to a natural killer cell.